Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Interaction between the HPV-16 E2 transcriptional activator and p53

Oncogene volume 18, pages 7748–7754 (1999)Cite this article

Abstract

The HPV-16 E2 protein is a major regulator of viral DNA replication and gene expression. Through interactions with the viral origin binding protein, E1, it localizes E1 to the origin of replication and stimulates the initiation of viral DNA replication. However, several recent reports have described a number of diverse activities of E2 relating to the induction of apoptosis through both p53 dependent and independent mechanisms, and to induction of growth arrest in both the G1 and G2M phases of the cell cycle. Recent studies have also shown that p53 can specifically inhibit HPV DNA replication, albeit through an unknown mechanism. Since p53 has been described in the replication centres of Herpes Viruses, Adenovirus and SV40 we decided to investigate whether any of the above activities of E2 may be related to an association with p53. We show, in a series of in vitro assays, specific interaction between p53 and HPV-16 E2 via residues in the carboxy terminal half of the E2 protein. Mutational analysis of p53 indicates that sequences in both the DNA binding and oligomerization domains are essential for the interaction, and a mutant of p53 which is unable to bind E2 is also unable to inhibit HPV DNA replication. Finally, using an inducible system of p53 expression we also show that E2 will complex with p53 in vivo. These results raise the intriguing possibility that p53 may also be involved in HPV DNA replication centres, and also provides explanations for some of the diverse activities reported for the HPV E2 proteins.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Androphy EJ, Lowy DR and Schiller JT. . 1987a Nature 325: 70–73.

  • Androphy EJ, Hubbert NL, Schiller JT and Lowy DR. . 1987b EMBO J. 6: 989–992.

  • Banks L, Matlashewski G and Crawford L. . 1986 Eur. J. Biochem. 159: 529–534.

  • Banks L, Spence P, Androphy E, Hubbert N, Matlashewski G, Murray A and Crawford L. . 1987 J. Gen. Virol. 68: 1351–1359.

  • Bargonetti J, Reynisdottir I, Friedman PN and Prives C. . 1992 Genes Dev. 6: 1886–1898.

  • Bouvard V, Storey A, Pim D and Banks L. . 1994 EMBO J. 13: 5451–5459.

  • Braithwaite AW, Sturzbecher HW, Addison C, Palmer C, Rudge K and Jenkins J. . 1987 Nature 329: 458–460.

  • Cripe TP, Haugen TH, Turk JP, Tabatabai F, Schmid PG, Durst M, Gissmann L, Roman A and Turek LP. . 1987 EMBO J. 6: 3745–3753.

  • Danielian P, White R, Hoare S, Fawell S and Parker M. . 1993 Mol. Endocrinol. 7: 232–240.

  • Desaintes C, Demeret C, Goyat S, Yaniv M and Thierry F. . 1997 EMBO J. 16: 504–515.

  • Frattini MG, Hurst SD, Lim HB, Swaminathan S and Laimins LA. . 1997 EMBO J. 16: 318–331.

  • Fortunato EA and Spector DH. . 1998 J. Virol. 72: 2033–2039.

  • Gannon JV and Lane DP. . 1987 Nature 329: 456–458.

  • Giri I and Yaniv M. . 1988 EMBO J. 7: 2823–2829.

  • Goodwin EC, Naeger LK, Breiding DE, Androphy EJ and DiMaio D. . 1998 J. Virol. 72: 3925–3934.

  • Hedge RS, Grossman SR, Laimins LA and Sigler PB. . 1992 Nature 359: 505–512.

  • Hwang ES, Naeger LK and DiMaio D. . 1996 Oncogene 12: 795–803.

  • Konig C, Roth J and Dobbelstein M. . 1999 J. Virol. 73: 2253–2262.

  • Kovelman R, Bilter GK, Glezer E, Tsou AY and Barbosa MS. . 1996 J. Virol. 70: 7549–7560.

  • Lepik D, Ilves I, Kristjuhan A, Maimets T and Ustav M. . 1998 J. Virol. 72: 6822–6831.

  • Littlewood TD, Hancock DC, Danielian PS, Parker MG and Evan GI. . 1995 Nucl. Acids Res. 23: 1686–1690.

  • Lu J, Sun YN, Rose RC, Bonnez W and McCance DJ. . 1993 J. Virol. 67: 7131–7139.

  • Matlashewski G, Schneider J, Banks L, Jones N, Murray A and Crawford L. . 1987 EMBO J. 6: 1741–1746.

  • Piccini A, Storey A, Massimi P and Banks L. . 1995 J. Gen. Virol. 61: 1630–1638.

  • Piccini A, Storey A, Romanos M and Banks L. . 1997 J. Gen. Virol. 78: 1963–1970.

  • Pim D, Massimi P and Banks L. . 1997 Oncogene 15: 257–264.

  • Prakesh S, Grossman SR, Pepinsky R, Laimins LA and Androphy EJ. . 1992 Genes Dev. 6: 105–116.

  • Pratt WB. . 1990 Mol. Cell. Endocrinol. 74: C69–C76.

  • Querido E, Marcellus RC, Lai A, Charbonneau R, Teodor JG, Ketner G and Branton PE. . 1997 J. Virol. 71: 3788–3798.

  • Remm M, Brain R and Jenkins JR. . 1992 Nucl. Acids Res. 20: 6015–6021.

  • Sakai H, Toshiharu Y, Benson JD, Dowhanick JJ and Howley PM. . 1996 J. Virol. 70: 1602–1611.

  • Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM. . 1990 Cell 63: 1129–1136.

  • Sedman J and Stenlund A. . 1995 EMBO J. 14: 6218–6228.

  • Sedman J and Stenlund A. . 1996 EMBO J. 15: 5085–5092.

  • Steegenga WT, Riteco N, Jochemsen AG, Fallaux FJ and Bos JL. . 1998 Oncogene 16: 349–357.

  • Steger G and Corbach S. . 1997 J. Virol. 71: 50–58.

  • Swindle CS, Zou N, Van Tine BA, Shaw GM, Engler JA and Chow LT. . 1999 J. Virol. 73: 1001–1009.

  • Tarunina M and Jenkins JR. . 1993 Oncogene 8: 3165–3173.

  • Thomas M, Massimi P and Banks L. . 1996 Oncogene 13: 471–480.

  • Werness BA, Levine AJ and Howley PM. . 1990 Science 248: 76–79.

  • Wilcock D and Lane DP. . 1991 Nature 349: 429–431.

  • Yew PR, Liu X and Berk AJ. . 1994 Genes Dev. 8: 190–202.

  • Zhong L and Hayward GS. . 1997 J. Virol. 71: 3146–3160.

Download references

Acknowledgements

We are most grateful to Bert Vogelstein who kindly provided the trp248 mutant and to Miranda Thomas for comments on the manuscript. The work presented here was partly funded by the Associazione Italiana per la Ricerca sul Cancro.

Author information

Authors and Affiliations

  1. International Centre for Genetic Engineering and Biotechnology, Padriciano 99, Trieste, I-34012, Italy

    Paola Massimi, David Pim, Cosetta Bertoli & Lawrence Banks

  2. Laboratoire de Cancérogénèse Moléculaire, UMR 217 du CNRS, DRR, DSV, Centre d'Etude Nucléaire, CEA, 92265, Fontenay aux Roses Cedex, France

    Véronique Bouvard

Authors
  1. Paola Massimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Pim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cosetta Bertoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Véronique Bouvard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lawrence Banks
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Massimi, P., Pim, D., Bertoli, C. et al. Interaction between the HPV-16 E2 transcriptional activator and p53. Oncogene 18, 7748–7754 (1999). https://doi.org/10.1038/sj.onc.1203208

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203208

Keywords

This article is cited by

Search

Advanced search

Quick links